Navigation Links
Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
Date:1/8/2013

e CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus remarked, “The FDA decision to approve lomitapide provides a new option for patients with HoFH, who so often develop extensive atherosclerotic cardiovascular disease as children, and remain inadequately treated.” Christie Ballantyne, MD, co-chair of the CMHC, chief, Section of Cardiovascular Research and Cardiology at Baylor College of Medicine and director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart and Vascular Center echoed a similar sentiment: “I am excited that we will have a new treatment option available for patients with HoFH.”

Sergio Fazio, MD, PhD, the Cornelius Vanderbilt Professor of Medicine and Pathology at Vanderbilt University School of Medicine in Nashville, Tenn., and chief of the Section of Cardiovascular Disease Prevention, cited the significance of the lomitapide approval: “This novel therapy is at the other end of the spectrum of cholesterol-lowering therapies – not a drug for everyone, like the statins, but an extreme intervention for extreme situations. Its mechanism of action is based on the inhibition of MTP, an intracellular protein that moves the lipid droplet to the forming lipoprotein in the liver and intestine. By targeting lipoprotein assembly, lomitapide has the power to reduce cholesterol irrespective of the type of mutation causing FH, since its effect is not based on up-regulation of the LDL receptor.”

Convening Oct. 2–5, 2013, in Boston, the CMHC is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including cardiovascular disease, obesity, type 2 diabetes, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

For more information, contac
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Midwest Healthcare Startups Raise $996 Million in 2012
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
4. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
5. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
6. Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain
7. The Medzilla Employment Report for December, 2012: Unemployment Drops to Lowest Rate in 4 Years; Experts Predict Unprecedented Growth in Healthcare IT
8. Life Solutions Advocates Announces New Partnerships in Health Promotion and Disease Prevention Initiative
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
10. Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
11. Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)...  Saddleback Memorial Medical Center in Laguna ... on the West Coast to perform a hysterectomy using ... women with a state-of-the-art, minimally invasive approach to gynecological ... , M.D., a highly regarded Orange County ... minimally invasive surgery at Saddleback Memorial, led the surgical ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... S.A. and,Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary ... partnership agreement for the,promotion and distribution of Stallergenes ... of Independent States (CIS). , ... and a strong demand on the,part of the ...
... Md., March 24 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that certain ... of its common stock and warrants in a registered ... agreements, PharmAthene will sell an aggregate of 2,116,055 newly ...
... easy and safe for everyone--including Mother Earth , ... ... now have more free time following the invention of the FlameDisk, ... solid ethanol as its fuel source, lights instantaneously with the touch ...
Cached Biology Technology:Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3PharmAthene Announces $5.5 Million Public Equity Offering 2PharmAthene Announces $5.5 Million Public Equity Offering 3Just Say No To Charcoal! New Eco-Friendly Alternative Grills Faster, Burns Cleaner And Greener 2
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... release is available in German . ... that are crucial in fighting pathogen assault. Researchers ... the Helmholtz Centre for Environmental Research (UFZ) characterized ... class II locus in a tailed amphibian. Unlike ...
... Manchester has been successful in gaining major European ... millions of biological samples, such as DNA, can ... across Europe. The Centre for Integrated Genomic ... Translational Medicine, is playing a key role in ...
... CA Nitrogen is essential to all life on Earth, and ... determine how ecosystems respond to global warming. But certain aspects ... puzzled scientists, defying, in a sense, the laws of supply ... atmosphere often thrive where it is readily available in the ...
Cached Biology News:New findings on immune system in amphibians 2Manchester clears first hurdle in €170 million biobank building boom 2Researchers explain nitrogen paradox in forests 2